Answers are grounded in this paper and cite their sources.
The capability of lipid-based nanoparticles (LBNs) to revolutionise cancer therapy is examined in this article. The potential of lipid-based nanoparticles (LBNs) to revolutionise cancer therapy is examined in this article. Before moving on to the formulation, characterization, and therapeutic applications of LBN, a brief discussion of the importance of targeted drug delivery is given. Liposomal delivery systems (LBNs), incorporating solid lipid nanoparticles (SLNs), liposomes and nanostructured lipid carriers, offer a versatile platform for accurate drug delivery (NLCs). The article discusses the potential of liquid nanoparticles (LBNs) in cancer therapy, highlighting their stability, storage, and techniques like reverse phase evaporation, thin-film hydration, and microemulsions. It also explores their physical characteristics, drug release studies, and role in tailored treatments. The review highlights manufacturing challenges and regulatory concerns while highlighting the evolving field of LBN applications.
No takes yet. Share an insight, caveat, or question.
Saha et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: